Cabaletta Bio (CABA) Projected to Post Earnings on Thursday

Key Points

• Cabaletta Bio (CABA)** is set to release its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.71) per share and revenues of $4.17 million.
• The company's recent stock performance shows a 52-week low of $0.99 and a high of $6.73, with current trading around $1.45.
• Analyst ratings vary, with the consensus rating as "Buy" and a target price of $14.43, despite recent price target adjustments from brokerages such as Citigroup and Guggenheim.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect Cabaletta Bio to post earnings of ($0.71) per share and revenue of $4.17 million for the quarter.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.02). On average, analysts expect Cabaletta Bio to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cabaletta Bio Stock Performance

CABA stock traded down $0.09 during mid-day trading on Friday, hitting $1.36. The company had a trading volume of 1,222,354 shares, compared to its average volume of 964,542. The firm has a market cap of $69.01 million, a PE ratio of -0.50 and a beta of 2.74. The stock's fifty day moving average price is $1.73 and its two-hundred day moving average price is $1.73. Cabaletta Bio has a 12 month low of $0.99 and a 12 month high of $6.26.

Analyst Upgrades and Downgrades

CABA has been the subject of several recent research reports. HC Wainwright reiterated a "buy" rating and issued a $25.00 target price on shares of Cabaletta Bio in a research note on Wednesday, June 11th. Citigroup reduced their target price on shares of Cabaletta Bio from $17.00 to $13.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Finally, Guggenheim lifted their target price on shares of Cabaletta Bio from $23.00 to $25.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $14.43.

Hedge Funds Weigh In On Cabaletta Bio

Hedge funds have recently bought and sold shares of the company. Comerica Bank grew its stake in Cabaletta Bio by 2,292.1% during the first quarter. Comerica Bank now owns 41,599 shares of the company's stock valued at $58,000 after acquiring an additional 39,860 shares in the last quarter. Invesco Ltd. grew its stake in Cabaletta Bio by 357.1% during the first quarter. Invesco Ltd. now owns 61,675 shares of the company's stock valued at $85,000 after acquiring an additional 48,181 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new position in Cabaletta Bio during the first quarter valued at approximately $102,000.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.